Symptom–metabolic topography on brain fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography: associations between presenting clinical features and regional hypometabolism

Alev Çınar; Aslı Ayan

Symptom–metabolic topography on brain fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography: associations between presenting clinical features and regional hypometabolism

Abstract

Aims: Brain 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) provides functional information on regional cerebral glucose metabolism and may support evaluation of cognitive impairment. This study investigated associations between presenting clinical features and the topographic distribution of CortexID-derived regional hypometabolism in patients undergoing dementia-related brain 18F-FDG PET/CT. Methods: This retrospective exploratory study included 53 patients scanned at a tertiary referral center between January 2017 and January 2021. Presenting clinical features were coded as present or absent, and images were assessed visually and by CortexID semiquantitative analysis. Regions with a Z-score ≤-2.5 were classified as significantly hypometabolic. Associations were evaluated using Fisher’s exact test, odds ratios with 95% confidence intervals, Benjamini–Hochberg false discovery rate (FDR) correction, Spearman rank correlation, and supportive age- and gender-adjusted logistic regression. Results: The mean age was 66.1±4.7 years, and 46 patients (86.8%) were male. Memory complaint was most frequent (69.8%) and showed nominal associations with parietal, temporal, and combined parietotemporal patterns, whereas speech disturbance showed nominal associations with frontal hypometabolism, particularly the left frontal region. These associations remained directionally consistent in age- and gender-adjusted models but none survived FDR correction across the complete regional or composite-pattern families (lowest adjusted q=0.103). Symptom burden was uncorrelated with the number of threshold positive hypometabolic regions (Spearman ρ=0.035, p=0.805). Conclusion: Presenting memory and speech-related symptoms showed anatomically coherent but multiplicity-sensitive associations with regional hypometabolic topography on brain 18F-FDG PET/CT. These hypothesis-generating findings support prospective investigation using standardized neuropsychological phenotyping, continuous quantitative PET measures, and independent etiological characterization.

Keywords

Supporting Institution

NONE

Ethical Statement

UPLOADED

References

Arbizu J, Morbelli S, Minoshima S, et al. SNMMI procedure standard/EANM practice guideline for brain [18F]FDG PET imaging, version 2.0. J Nucl Med. 2025;66(Suppl 2):S45-S60. doi:10.2967/jnumed.124.268754
Guedj E, Varrone A, Boellaard R, et al. EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3. Eur J Nucl Med Mol Imaging. 2022;49(2):632-651. doi:10.1007/s00259-021-05603-w
Shivamurthy VKN, Tahari AK, Marcus C, Subramaniam RM. Brain FDG PET and the diagnosis of dementia. AJR Am J Roentgenol. 2015; 204(1):W76-W85. doi:10.2214/AJR.13.12363
Ishii K. PET approaches for diagnosis of dementia. AJNR Am J Neuroradiol. 2014;35(11):2030-2038. doi:10.3174/ajnr.A3695
Mosconi L, Tsui WH, Herholz K, et al. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med. 2008;49(3):390-398. doi:10.2967/jnumed.107.045385
Womack KB, Diaz-Arrastia R, Aizenstein HJ, et al. Temporoparietal hypometabolism in frontotemporal lobar degeneration and associated imaging diagnostic errors. Arch Neurol. 2011;68(3):329-337. doi:10.1001/archneurol.2010.295
Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med. 1995;36(7): 1238-1248.
Herholz K, Salmon E, Perani D, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage. 2002;17(1):302-316. doi:10.1006/nimg.2002.1208

Fällmar D, Lilja J, Danfors T, et al. Z-score maps from low-dose 18F-FDG PET of the brain in neurodegenerative dementia. Am J Nucl Med Mol Imaging. 2018;8(4):239-246.
Palop JJ, Chin J, Mucke L. A network dysfunction perspective on neurodegenerative diseases. Nature. 2006;443(7113):768-773. doi:10.1038/nature05289
Sala A, Perani D. Brain molecular connectivity in neurodegenerative diseases: recent advances and new perspectives using positron emission tomography. Front Neurosci. 2019;13:617. doi:10.3389/fnins.2019.00617
Yakushev I, Drzezga A, Habeck C. Metabolic connectivity: methods and applications. Curr Opin Neurol. 2017;30(6):677-685. doi:10.1097/WCO.0000000000000494
Ding Y, Sohn JH, Kawczynski MG, et al. A deep learning model to predict a diagnosis of Alzheimer disease by using 18F-FDG PET of the brain. Radiology. 2019;290(2):456-464. doi:10.1148/radiol.2018180958
Etminani K, Soliman A, Davidsson A, et al. A 3D deep learning model to predict the diagnosis of dementia with Lewy bodies, Alzheimer's disease, and mild cognitive impairment using brain 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2022;49(2):563-584. doi:10.1007/s00259-021-05483-0
Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):535-562. doi:10.1016/j.jalz.2018.02.018
Prestia A, Caroli A, van der Flier WM, et al. Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Neurology. 2013;80(11):1048-1056. doi:10.1212/WNL.0b013e3182872830
Silverman DHS, Small GW, Chang CY, et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA. 2001;286(17):2120-2127. doi:10.1001/jama.286.17.2120
Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol. 1995;57(1):289-300. doi:10.1111/j.2517-6161.1995.tb02031.x
Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol. 1997;42(1):85-94. doi:10.1002/ana.410420114
Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease: FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging. 2005;32(4):486-510. doi:10.1007/s00259-005-1762-7
Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11): 1006-1014. doi:10.1212/WNL.0b013e31821103e6
Mirbod M, Ayubcha C, Werner TJ, et al. FDG-PET in the diagnosis of primary progressive aphasia: a systematic review. Ann Nucl Med. 2024; 38:673-687. doi:10.1007/s12149-024-01958-w
Rabinovici GD, Jagust WJ, Furst AJ, et al. Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol. 2008;64(4):388-401. doi:10.1002/ana.21451
Nobili F, Arbizu J, Bouwman F, et al. European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain 18F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus. Eur J Neurol. 2018;25(10):1201-1217. doi:10.1111/ene.13728
McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88-100. doi:10.1212/WNL.0000000000004058
Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(Pt 9):2456-2477. doi:10.1093/brain/awr179
Dukart J, Mueller K, Horstmann A, et al. Differential effects of global and cerebellar normalization on detection and differentiation of dementia in FDG-PET studies. Neuroimage. 2010;49(2):1490-1495. doi:10.1016/j.neuroimage.2009.09.017
Borghammer P, Cumming P, Aanerud J, Gjedde A. Artefactual subcortical hyperperfusion in PET studies normalized to global mean: lessons from Parkinson's disease. Neuroimage. 2009;45(2):249-257. doi:10.1016/j.neuroimage.2008.07.042
Park JC, Lim H, Byun MS, et al. Sex differences in the progression of glucose metabolism dysfunction in Alzheimer's disease. Exp Mol Med. 2023;55(5):1023-1032. doi:10.1038/s12276-023-00993-3

Details

Primary Language

English

Subjects

Nuclear Medicine

Journal Section

Research Article

Authors

Alev Çınar ^*
0000-0002-3426-2987
Türkiye

Aslı Ayan
0000-0001-6311-1785
Türkiye

Publication Date

October 25, 2026

Submission Date

July 8, 2026

Acceptance Date

August 26, 2026

Published in Issue

Year 2026 Volume: 7 Number: 5

IZ

https://izlik.org/JA29RN64SG

Cite

RIS / Bibtex

APA

Çınar, A., & Ayan, A. (2026). Symptom–metabolic topography on brain fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography: associations between presenting clinical features and regional hypometabolism. Journal of Medicine and Palliative Care, 7(5), 942-949. https://izlik.org/JA29RN64SG

AMA

1.Çınar A, Ayan A. Symptom–metabolic topography on brain fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography: associations between presenting clinical features and regional hypometabolism. J Med Palliat Care / JOMPAC / jompac. 2026;7(5):942-949. https://izlik.org/JA29RN64SG

Chicago

Çınar, Alev, and Aslı Ayan. 2026. “Symptom–metabolic Topography on Brain Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography Computed Tomography: Associations Between Presenting Clinical Features and Regional Hypometabolism”. Journal of Medicine and Palliative Care 7 (5): 942-49. https://izlik.org/JA29RN64SG.

EndNote

Çınar A, Ayan A (October 1, 2026) Symptom–metabolic topography on brain fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography: associations between presenting clinical features and regional hypometabolism. Journal of Medicine and Palliative Care 7 5 942–949.

IEEE

[1]A. Çınar and A. Ayan, “Symptom–metabolic topography on brain fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography: associations between presenting clinical features and regional hypometabolism”, J Med Palliat Care / JOMPAC / jompac, vol. 7, no. 5, pp. 942–949, Oct. 2026, [Online]. Available: https://izlik.org/JA29RN64SG

ISNAD

Çınar, Alev - Ayan, Aslı. “Symptom–metabolic Topography on Brain Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography Computed Tomography: Associations Between Presenting Clinical Features and Regional Hypometabolism”. Journal of Medicine and Palliative Care 7/5 (October 1, 2026): 942-949. https://izlik.org/JA29RN64SG.

JAMA

1.Çınar A, Ayan A. Symptom–metabolic topography on brain fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography: associations between presenting clinical features and regional hypometabolism. J Med Palliat Care / JOMPAC / jompac. 2026;7:942–949.

MLA

Çınar, Alev, and Aslı Ayan. “Symptom–metabolic Topography on Brain Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography Computed Tomography: Associations Between Presenting Clinical Features and Regional Hypometabolism”. Journal of Medicine and Palliative Care, vol. 7, no. 5, Oct. 2026, pp. 942-9, https://izlik.org/JA29RN64SG.

Vancouver

1.Alev Çınar, Aslı Ayan. Symptom–metabolic topography on brain fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography: associations between presenting clinical features and regional hypometabolism. J Med Palliat Care / JOMPAC / jompac [Internet]. 2026 Oct. 1;7(5):942-9. Available from: https://izlik.org/JA29RN64SG